Effect of setting of drug holidays on the efficacy of weekly higher shorter plus lower continuous (metronomic) five-fluorouracil (5-FU) concentration regimen in colorectal cancer

被引：0
|
作者：
Yoshikawa, R. [1 ]
Hashimoto-Tamaoki, T. [1 ]
Gega, M. [1 ]
Yagyu, T. [1 ]
Noda, M. [1 ]
Yanagi, H. [1 ]
机构：
[1] Hyogo Coll Med, Nishinomiya, Hyogo 6638501, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.13542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13542
引用
收藏
页数：1
相关论文
共 21 条
  • [1] WEEKLY REGIMEN OF 5-FU VS 5-FU PLUS INTERMEDIATE DOSE FOLINIC ACID IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    MARTONI, A
    CRICCA, A
    GUARALDI, M
    COVIZZI, M
    FARRIS, A
    PANNUTI, F
    ANTICANCER RESEARCH, 1992, 12 (03) : 607 - 612
  • [2] 120-HOUR 5-FLUOROURACIL (5-FU) CONTINUOUS INFUSION (CI) PLUS BCNU IN ADVANCED COLORECTAL-CANCER
    VILLARGRIMALT, A
    CANDEL, MT
    DELGADO, F
    GARCIAREINOSO, J
    SANCHIS, C
    VICIANO, V
    ASENCIO, F
    MARTINEZABAD, M
    AGUILO, J
    SANCHEZ, JJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (05): : 387 - 392
  • [3] Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid
    Joulia, JM
    Pinguet, F
    Ychou, M
    Duffour, J
    Astre, C
    Bressolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 296 - 301
  • [4] A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer
    Kotake, K
    Ohashi, Y
    Kodaira, S
    Koyama, Y
    ONCOLOGY REPORTS, 2005, 14 (01) : 129 - 134
  • [5] A combination of continuous infusion (Cl) 5-fluorouracil (5-FU) and weekly docetaxel: An active regimen for elderly patients (pts) with advanced or metastatic cancer of the stomach and distal esophagus.
    Chun, H
    Puccio, C
    Mittelman, A
    ANNALS OF ONCOLOGY, 2000, 11 : 66 - 66
  • [6] Results of the phase II portion of a phase I/II study of pemetrexed plus irinotecan in patients with advanced colorectal cancer previously treated with a 5-fluorouracil (5-FU)-containing regimen
    Kettner, Erika
    Kroening, Hendrik
    Hochster, Howard
    Becker, Klaus
    Peschel, Christian
    Ramanathan, Ramesh K.
    Macdonald, Jack
    Hong, Shengyan
    John, Bill
    Schmoll, Hans-Joachim
    ANNALS OF ONCOLOGY, 2004, 15 : 85 - 86
  • [7] A PROSPECTIVE RANDOMIZED TRIAL OF CONTINUOUS INFUSION 5-FLUOROURACIL (5-FU) VERSUS 5-FU PLUS CISPLATIN IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A TRIAL OF THE SPANISH-COOPERATIVE-GROUP FOR DIGESTIVE-TRACT TUMOR-THERAPY (TTD)
    DIAZRUBIO, E
    JIMENO, J
    ANTON, A
    ARANDA, E
    SANCHEZ, J
    MASSUTI, B
    CRUZHERNANDEZ, J
    CARRATO, A
    MARTIN, M
    BELON, J
    GONZALEZ, R
    MILLA, A
    SANCHIZ, F
    BALANA, C
    LIZON, J
    DIAZFAES, J
    ALONSO, A
    NAVARRETE, A
    ORTIZ, JS
    CAMPS, C
    DELMORAL, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (01): : 56 - 60
  • [8] Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG15021
    Ueda, A.
    Muranaka, T.
    Kawamoto, Y.
    Sawada, K.
    Nakatsumi, H.
    Harada, K.
    Kobayashi, Y.
    Miyagishima, T.
    Hatanaka, K.
    Dazai, M.
    Kawahata, S.
    Sasaki, T.
    Sasaki, Y.
    Kato, S.
    Shinada, K.
    Tsuji, Y.
    Yuki, S.
    Sakamoto, N.
    Nishimoto, N.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 48 - 48
  • [9] Oxaliplatin (L-OHP) combined with continous infusion 5-fluorouracil (5-FU) and folinic acid (FA) based regimen in advanced colorectal cancer patients, confirmatory data on efficacy and toxicity
    Bochicchio, AM
    Capobianco, AML
    Coccaro, M
    Colasuonno, L
    Di Leo, P
    Galasso, R
    ANNALS OF ONCOLOGY, 2000, 11 : 64 - 64
  • [10] Multi-centered phase II trial of weekly 5-FU plus I-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
    Sasaki, Y.
    Muranaka, T.
    Kawamoto, Y.
    Sawada, K.
    Nakatsumi, H.
    Harada, K.
    Miyagishima, T.
    Hatanaka, K.
    Dazai, M.
    Ueda, A.
    Sasaki, T.
    Shinada, K.
    Tsuji, Y.
    Yuki, S.
    Sakamoto, N.
    Nishimoto, N.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2019, 30
123